India, May 13 -- A new 36-month update from UroGen Pharma's (URGN) pivotal Phase 3 ENVISION trial showed that many patients who achieved an early complete response with ZUSDURI (mitomycin) remained disease-free through three years, reinforcing the therapy's durability in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
The analysis found a 64.5% probability of remaining event-free at 36 months among patients who achieved a complete response at three months, based on Kaplan-Meier estimates.
At a median follow-up of 35.5 months, the median duration of response has not yet been reached, indicating that responses continue beyond the current observation window.
Investigators noted that the durability was...